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Head and neck squamous cell carcinoma (HNSCC) is a common type of cancer. Better understanding
of molecular aberrations associated with HNSCC might identify new diagnostic and therapeutic
strategies for this disease. In this study, we found ubiquitin-speciﬁc protease 4 (USP4) was signiﬁ-
cantly upregulated in HNSCC. USP4 negatively regulates RIP1-mediated NF-jB activation and pro-
motes TNF-a-induced apoptosis in FaDu cells. USP4 directly interacts with receptor-interacting
protein 1 (RIP1) and deubiquitinates K63-linked ubiquitination from RIP1. Therefore, our results
indicate that USP4 has tumor suppressor roles in HNSCC and suggest USP4 as a potential therapeutic
target for HNSCC.
Structured summary of protein interactions:
RIP1 physically interacts with USP4 by anti tag coimmunoprecipitation (View Interaction: 1, 2, 3)
RIP1 physically interacts with USP4 by anti bait coimmunoprecipitation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction well as inﬂammation and tumorigenesis and has been implicatedHead and neck cancer encompasses epithelial malignancies that
arise in the paranasal sinuses, nasal cavity, oral cavity, pharynx,
and larynx [1]. Almost all of these epithelial malignancies are head
and neck squamous cell carcinoma (HNSCC) [1]. Head and neck
cancer is the sixth most common type of cancer, representing
about 6% of all cases and accounting for an estimated 650000
new cancer cases and 350000 cancer deaths worldwide every year
[1,2]. Achieving a better understanding of molecular aberrations
associated with HNSCC might identify new diagnostic and thera-
peutic strategies for this disease.
Apoptosis is a crucial cellular response that plays a crucial role
in shaping our body during development and in regulating tissue
homeostasis by eliminating unwanted cells [3]. Tumor necrosis
factor (TNF) has been known as a major mediator of apoptosis asin the pathogenesis of a wide spectrum of human diseases [3].
Upon binding to its TNF receptor type 1 (TNFR1), TNF-a induces
sequential formation of two spatially distinct signaling complexes
[4]. First, TNFR1 recruits RIP1 and TRAF2 in complex I, which has
been proposed to promote survival and inﬂammation via the acti-
vation of the transcription factor NF-jB [4,5]. A crucial event in this
function is the conjugation of K63-linked polyubiquitin chains to
RIP1. These chains function as scaffolds for the assembly of TAK1
kinase and TAK1-binding proteins 1 and 2 (TAB1 and TAB2).
TAK1 stimulates inhibitor of jB (IjB) kinase (IKK), which consists
of the catalytic subunits IKK-a and b and the regulatory subunit
IKK-c (NEMO). The TAK1-TAB1-TAB2 and IKKa-IKKb-IKKc signal-
ing complexes then mediate activation of NF-jB leading to the
expression of anti-apoptosis proteins such as cFLIP and IAP and
promote cell survival [4,5]. The second complex (complex II) in-
volves TRADD, FADD and procaspase-8 and -10, forms in the cyto-
plasm and initiates apoptosis [4]. RIP1 ubiquitylated in complex I
and the subsequent de-ubiquitylation is required for the associa-
tion of RIP1 with complex II [6,7]. The balance between apoptotic
and proliferative outcomes could be regulated by RIP1 ubiquityla-
tion state [6,7].
Deubiquitination is catalyzed by deubiquitinating enzymes
(DUBs), which are proteases that cleave ubiquitin or ubiquitin-like
proteins from target proteins [8]. The human genome encodes
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based on their Ub-protease domains. The ubiquitin-speciﬁc prote-
ases (USP) represent the largest subclass of DUBs [8]. As a member
of USP family, USP4 has been identiﬁed to deubiquitinate K63-
linked ubiquitin conjugates from TRAF2, TRAF6 and TAK1 [9–11]
and stabilizes molecules by deubiquitinating K48-linked ubiquiti-
nation [12–14]. For example, USP4 directly interacts with and
deubiquitylates transforming growth factor-b (TGF-b) type I recep-
tor (TbRI), thereby determining the levels of TGF-b signaling [13].
USP4 binds to and deubiquitinates adenosine A2A receptor and en-
hances cell surface level of the receptor [14].
In this study, we demonstrated that USP4 negatively regulated
RIP1-mediated NF-jB activation and promoted TNF-a-induced
apoptosis through interacting with RIP1 and deubiquitinating
K63-linked ubiquitination from RIP1.
2. Materials and methods
2.1. Tissue samples
HNSCC tissues and its matched non-tumor tissues were ob-
tained from 20 HNSCC patients treated at the Department of Oto-
rhinolaryngology, General Hospital of Jinan Military Region of PLA
in China. All samples were collected with patients’ informed con-
sent, conﬁrmed by the pathological examination and all of the
experiments were approved by the Internal Review and Ethics
Boards of the General Hospital of Jinan Military Region of PLA.
2.2. Cell culture, reagent and plasmids
HEK293 andhumanhead andneck cancer cell line FaDuwere ob-
tained from American Type Culture Collection (Manassas, VA). The
cells were cultured at 37 C under 5% CO2 in DMEM supplemented
with 10% FCS (Invitrogen-Gibco), 100 U/ml penicillin, and 100 lg/
ml streptomycin. TNF-awas from PeproTech (Rocky Hill, NJ). Cyclo-
heximide (CHX), MG132 and the antibodies for USP4 and Flag wereFig. 1. USP4 expression is up-regulated in HNSCC. (A) Relative expression of USP4 in 20 s
by qRT-PCR. Data are shown as DDCt values. (B) The mean and standard deviation of U
tumor tissues were shown. shown. Data are presented as 2DCt values (, p < 0.01). (C) Ex
available HNSCC protein samples. N, matched non-tumor tissue; T, HNSCC tissue.from Sigma (St. Louis, MO). The antibody speciﬁc for cleaved Casp8
was from Anbo Biotechnology. The antibodies speciﬁc for HA, Myc,
Ub, RIP1, GAPDH, horseradish peroxidase-conjugated secondary
antibodies, and protein G agarose used for immunoprecipitation
were from Santa Cruz Biotechnology (Santa Cruz, CA). pCMV6-
Flag-USP4 expression plasmid was purchased from OriGene (Rock-
ville, MD). USP4 cDNA was subcloned into pCMV-Myc plasmids
(Promega). The USP4 C311S mutation was generated using the
KOD-Plus-Mutagenesis kit (Toyobo, Osaka, Japan) as previously de-
scribed [15]. HA-tagged USP4 mutants were provided by Dr. Ping
Wang (East China Normal University, China). NF-jB reporter plas-
mid, expression plasmids for RIP1, TRAF6, HA-Ub WT and mutant
K48, K63 were obtained as previously described [16].
2.3. Transfection and luciferase assay
For transient silencing, duplexes of small interfering RNA were
transfected into cells with the lipo2000 Transfection Reagent
(Invitrogen) according to the standard protocol. Target sequences
for transient silencing were 50-GCUGGGACAUGUACAAUGU-30 (siR-
NA 1), 50-GGCUCUGGAACAAAUACAU-30 (siRNA 2), and 50-GGUCG-
CAGAUGUGUAUAAU-30 (siRNA 3) for USP4, ‘scrambled’ control
sequences were 50-UUCUCCGAACGUGUCACGU-30. For stable selec-
tion of cell lines overexpressing USP4, transfected FaDu cells were
selected with the G418 (1000 lg/ml) and were pooled for further
experiments. For transient transfection of plasmids into HEK293
cells, jetPEI reagents were used (Polyplus-transfection). Luciferase
activity was measured with the Dual-Luciferase Reporter Assay
system according to the manufacturer’s instructions (Promega) as
described [15–17].
2.4. RNA quantiﬁcation
Total RNA was extracted with TRIzol reagent according to the
manufacturer’s instructions (Invitrogen) as described previously
[17]. The sequences of primers were 50-CCTGGGCTCTGTGGACurgical specimens of HNSCC tissues and matched non-tumor tissues was carried out
SP4 expression levels in 20 surgical specimens of HNSCC tissues and matched non-
pression of USP4 and GAPDH (internal control) were detected by western blot in six
Fig. 2. USP4 promotes TNF-a-induced apoptosis in HNSCC. (A) Western blot analysis of USP4 expression in FaDu cells stably transfected with HA-USP4 wild type (WT), HA-
USP4 C311S plasmid or control empty vector (Ctrl). (B) Cells as in (A) were treated with TNF-a (100 ng/ml) in the presence or absence of CHX (10 lg/ml). Cells were harvested
and stained with PI to quantify cell death. (C) Cells as in (A) were treated with TNF-a (100 ng/ml) in the presence of CHX (10 lg/ml) for 8 h. Cleaved Casp8 was detected by
Western blot. (D) Western blot and RT-PCR analysis of USP4 expression in FaDu cells transfected with control siRNA, USP4 siRNA 1, siRNA 2, or siRNA 3 for 36 h. (E) Cells as in
(D) were treated with TNF-a (100 ng/ml) in the presence or absence of CHX (10 lg/ml) overnight. Cells were harvested and stained with PI to quantify cell death. (F) FaDu
cells were transfected with control siRNA, or USP4 siRNA 2 plus 3 for 36 h and then treated with TNF-a (100 ng/ml) in the presence of CHX (10 lg/ml) for indicated time
periods. Cleaved Casp8 was detected by Western blot. , p < 0.05, , p < 0.01. Data are representative of three experiments (mean and SD of six samples in B and D).
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GTCATCCATGACAACTTTG03, 50-GTCCACCACCCTGTTGCTGTAG-30
for GAPDH.
2.5. Immunoprecipitation and western blot analysis
For immunoprecipitation (IP), whole-cell extracts were col-
lected 36 h after transfection and were lysed in IP buffer containing
1.0% (vol/vol) Nonidet P 40, 50 mM Tris–HCl, pH 7.4, 50 mM EDTA,
150 mM NaCl, and a protease inhibitor ‘cocktail’ (Merck). After
centrifugation for 10 min at 14000g, supernatants were collected
and incubated with protein G plus-agrose immunoprecipitation re-
agent together with 1 lg monoclonal anti-Flag or 1 lg anti-Myc.
After 6 h of incubation, beads were washed ﬁve times with IP buf-
fer. Immunoprecipitates were eluted by boiling with 1% (wt/vol)
SDS sample buffer. For western blot analysis, immunoprecipitates
or whole-cell lysates were loaded and subjected to SDS–PAGE,
transferred onto nitrocellulose membranes, and then blotted as de-
scribed previously [15–17].
2.6. Ubiquitination assays
Ubiquitination assays were performed as described [15]. For
analysis of the ubiquitination of RIP1, HEK293 cells were transfec-
ted with Myc-RIP1, HA-Ub (WT) or HA-Ub mutants and Flag-USP4,
and then whole-cell extracts were immunoprecipitated with anti-
Myc and analyzed by immunoblot with anti-HA antibody.
2.7. Cell death assay
The percentage of the SubG1 cell population was used to quan-
tify cell death. The supernatant and the adherent cells were har-
vested and resuspended in lysis buffer (0.1% sodium citrate and
0.1% Triton X-100 in PBS) containing propidium iodide (PI, Sigma,20 mg/ml). Cells were then analyzed using FACS (BD Biosciences)
with the CellQuest programme (BD Biosciences).
2.8. Statistical analysis
The differences between two groups were analyzed using Stu-
dent t test. A two-tailed value of p < 0.05 was considered statisti-
cally signiﬁcant.
3. Results
3.1. USP4 expression is up-regulated in HNSCC
Previous studies have shown that USP4 is overexpressed in var-
ious types of cancers such as lung, colon, thyroid, and urinary can-
cer [12,18]. To investigate whether USP4 expression is elevated in
HNSCC, we examined the expression levels of USP4 by quantitative
reverse transcription-PCR (qRT-PCR) in tumor tissues and its
matched non-tumor tissues from 20 HNSCC patients (Fig. 1A). As
shown in Fig. 1B, the average expression level of USP4 is signiﬁ-
cantly up-regulated in tumor tissues compared to matched non-tu-
mor tissues. Furthermore, in available HNSCC protein samples, we
conﬁrmed that USP4 protein level was also increased (Fig. 1C). To-
gether, these results provide strong evidence that USP4 is signiﬁ-
cantly upregulated in HNSCC.
3.2. USP4 promotes TNF-a-induced apoptosis in HNSCC
We then investigated the pathophysiological signiﬁcance and
its underlying mechanisms of the up-regulated USP4 in HNSCC.
FaDu stable cell line with USP4 overexpression was constructed
by transfecting HA-USP4 expression plasmid. Overexpression of
USP4 was conﬁrmed by western blotting with both USP4 and HA
antibodies (Fig. 2A). As shown in Fig. 2B, USP4 overexpression sig-
Fig. 3. USP4 targets RIP1. (A) FaDu cells were transfected with NF-jB reporter plasmid and USP4 plasmid, then treated with TNF-a (100 ng/ml) for 6 h and luciferase activity
was analyzed. (B) HEK293 cells were transfected with TRAF6 or RIP1, along with NF-jB reporter plasmid and USP4 plasmid, and luciferase activity was analyzed. (C) Lysates
from HEK293 cells transiently cotransfected with Myc-RIP1 and Flag-USP4 expression plasmids were subjected to immunoprecipitation with anti-Flag or anti-Myc antibody
followed by western blot analysis with anti-Myc or anti-Flag antibody, respectively. (D) Lysates from FaDu cells stimulated with TNF-a for indicated time periods were
subjected to immunoprecipitation with anti-RIP1 antibody followed by western blot analysis with anti-USP4 antibody. Proteins in whole-cell lysates were used as positive
control (Input). (E) Schematic diagram of USP4 WT and mutant constructs. USP4 Wild-type (WT) contains a DUSP domain and a C-terminal USP domain. N260 lacks C-
terminal USP domain. C261 lacks the DUSP domain. (F) Lysates from HEK293 cells transiently cotransfected with Myc-tagged RIP1 and HA-tagged USP4 mutants were
subjected to immunoprecipitation with anti-Myc antibody followed by western blot analysis with anti-HA antibody. Similar results were obtained in three independent
experiments. , p < 0.01. Data are representative of three experiments (mean and SD of six samples in A and B).
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TNF-a with CHX. In contrast, the USP4 point mutant (C311S) with-
out deubiquitinase activity lost the ability to promote cell apopto-
sis (Fig. 2B), indicating deubiquitinase activity is required for the
USP4-mediated promotion of TNF-a-induced apoptosis. Consistent
with above results, USP4 overexpression signiﬁcantly enhanced
caspase-8 activation induced by TNF-a plus CHX in FaDu cells
(Fig. 2C).
To further investigate the effect of endogenous USP4 on cell
apoptosis, three synthesized interfering RNAs targeting human
USP4 were used to suppress endogenous USP4 expression. USP4
expression was signiﬁcantly decreased in both mRNA and protein
level with transfection of USP4 speciﬁc siRNAs in FaDu cells
(Fig. 2D). USP4 knockdown in FaDu cells repressed cell apoptosis
(Fig. 2E). USP4 siRNA 2 and 3, which have higher efﬁciency to
knockdown USP4 expression (Fig. 2D), have greater potential to re-
press cell apoptosis (Fig. 2E). Consistently, USP4 knockdown mark-
edly reduced caspase-8 activity induced by TNF-a plus CHX in
FaDu cells (Fig. 2F). Collectively, these ﬁndings suggest that USP4
promotes TNF-a-induced apoptosis in HNSCC.3.3. USP4 targets RIP1
USP4 has been identiﬁed to repress TLR-, IL-1- and TNF-a-in-
duced NF-jB activation by deubiquitinating K63-linked ubiquitin
conjugates from TRAF2, TRAF6, and TAK1 [9–11]. To investigate
the up-regulation of USP4 correlates with the suppression of NF-
jB in HNSCC, we investigated whether USP4 had effects on TNF-
a-induced NF-jB activation in FaDu cells. As shown in Fig. 3A,
USP4 signiﬁcantly suppressed TNF-a-induced NF-jB activation in
FaDu cells. Furthermore, we found USP4 negatively regulated
RIP1-induced NF-jB activation (Fig. 3B). In order to study the
molecular mechanisms of USP4 on the inactivation of RIP1, the
interaction between these two proteins was investigated. Flag-
USP4 and Myc-RIP1 were cotransfected into HEK293 cells, 24 h
after transfection, immunoprecipitation experiments were per-
formed with Flag or Myc antibodies. As shown in Fig. 3C, Myc-
RIP1 was coprecipitated with Flag-USP4 using anti-Flag antibody
and vice versa. Endogenous interaction was also conﬁrmed in FaDu
cells stimulated with TNF-a for various times, followed by immu-
nopreicipitation assays with RIP1 antibody and western blotting
Fig. 4. USP4 removes K63-linked polyubiquitination conjugate from RIP1. (A) HEK293 cells were transiently cotransfected with Myc-RIP1, Flag-USP4 WT, or USP4 C311S and
HA-Ub plasmids and then stimulated with TNF-a for 30 min. Cell lysates were subjected to immunoprecipitation with anti-Myc antibody followed by western blot analysis
with anti-HA antibody. (B) Lysates from HEK293 cells transiently cotransfected with Myc-RIP1, Flag-USP4 or vector control and HA-Ub (K48) or HA-Ub (K63) or HA-Ub (WT)
plasmids were subjected to immunoprecipitation with anti-Myc antibody followed by western blot analysis with anti-HA antibody. (C) Lysates from HEK293 cells transfected
with control siRNA or USP4 siRNA 2 plus 3 and Myc-RIP1 and HA-Ub (WT) or HA-Ub (K63) or HA-Ub (K48) plasmids were subjected to immunoprecipitation with anti-Myc
antibody followed by western blot analysis with anti-HA antibody. (D) Lysates from FaDu cells transfected with control siRNA or USP4 siRNA 2 plus 3 and stimulated with
TNF-a for 60 min were subjected to immunoprecipitation with anti-RIP1 antibody followed by western blot analysis with anti-Ub antibody. Similar results were obtained in
three independent experiments.
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without TNF-a stimulation (Fig. 3D). As a control, the interaction
could not be detected with normal IgG. USP4 is composed of two
domains, the N-terminal DUSP domain and the C-terminal USP do-
main (Fig. 3E). Coimmunoprecipitation experiments showed that
RIP1 interacted with USP4 WT and C261, but not with N260, indi-
cating the C-terminal USP domain is required for the interaction
with RIP1 (Fig. 3F). Taken together, these data indicate RIP1 and
USP4 form a complex through the USP domain of USP4.
3.4. USP4 removes K63-linked polyubiquitination conjugate from RIP1
To test the role of USP4 in RIP1 ubiquitination, RIP1 was co-ex-
pressed with HA-ubiquitin and USP4 expression plasmids. USP4
WT remarkably decreased polyubiquitination of RIP1 with and
without TNF-a stimulation and USP4-C311S mutant failed to do
so (Fig. 4A), indicating USP4 has the deubiquitination ability to-
wards RIP1. In order to investigate the forms of USP4-mediated
deubiquitination of RIP, ubiquitin mutant vectors K48 and K63,
which contain arginine substitutions of all of its lysine residues ex-
cept the one at position 48 and 63, respectively, were used in the
transfection assays. As shown in Fig. 4B, transfection of ubiquitin
WT, K48 and K63 mutants could greatly increase the polyubiquiti-
nation of RIP1, consistent with the reported data that RIP1 could be
ubiquitinated through both K48- and K63-linked polyubiquitin
chains. But, cotransfection of USP4 greatly decreased the poly-
ubiqutination of RIP1 in the setting of ubiquitin WT or K63 trans-fected cells (Fig. 4B), but not in the K48-transfected cells (Fig. 4B),
indicating USP4 speciﬁcally deubiquitinates K63-linked polyubiqu-
itin chains from RIP1. To further conﬁrm USP4 deubiquitinates
K63-linked polyubiqutination of RIP1, USP4 siRNAs were transfec-
ted into HEK293 cells to knockdown endogenous USP4 expression.
The level of RIP1 polyubiqutination was greatly increased after
transfection of USP4 siRNA in the setting of WT and K63 ubiquitin
transfected cells, but not in the K48-transfected cells (Fig. 4C). To
conﬁrm USP4-mediated deubiquitination of RIP1 under physiolog-
ical conditions, we silenced USP4 expression by USP4 siRNAs trans-
fection in FaDu cells, followed by immunopreicipitation assays
with RIP1 antibody and western blotting with Ub antibody. As
shown in Fig. 4D, USP4 knockdown greatly increased TNF-a-in-
duced polyubiquitination of RIP1. All together, these data indicate
USP4 removes K63-linked polyubiquitin chains from RIP1, leading
to the inhibition of NF-jB activation and promotion of TNF-a-in-
duced apoptosis.
4. Discussion
USP4 is overexpressed in many types of cancers and the in-
creased levels of the USP4 appear to be having functional roles in
malignant cells. For example, USP4 promotes tumorigenesis when
overexpressed in mice [19]. USP4 interacts directly with and
deubiquitinates ADP-ribosylatibon factor-binding protein 1 (ARF-
BP1), leading to the stabilization of ARF-BP1 and subsequent
reduction of p53 levels [12]. These ﬁndings suggest an oncogenic
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are controversial. Some reports show USP4 is decreased in lung
cancer cell lines and it is not elevated in breast and pancreatic can-
cer [12,20]. Furthermore, USP4 is demonstrated as a negative reg-
ulator of Wnt signaling pathway [21], which has tumorigenesis
activity [22]. Recently, Xiao et al. reported that USP4 targeted
TRAF2 and TRAF6 for deubiquitination and inhibited TNF-a-in-
duced cancer cell migration [10]. In this study, we demonstrate
that USP4 is upregulated in HNSCC and promotes TNF-a-induced
apoptosis by targeting RIP1 for deubiquitination. Collectively,
these ﬁndings indicate that USP4 plays a tumor suppressor role.
Certainly, cancer cells would enhance the expression of multiple
molecules related to tumor progression. However, some molecules
having tumor suppressor roles will be upregulated by host cells
against cancer progression. The overexpression of USP4 in HNSCC
tissues may be modulated by host immune cells to promote apop-
tosis of cancer cells and attenuate cancer progression. The discrep-
ancy of USP4 in tumorigenesis might be due to the fact that
different type of tumor tissues and cancer cell lines are used in
these studies. Thus, the potential role of USP4 in tumorigenesis
in different type of tumors requires further investigation.
Ubiquitination state of RIP1 is critical for the balance between
cell apoptosis and proliferation. RIP1 can be modiﬁed by K63-
linked polyubiquitination, leading to the activation of TNF-a-in-
duced NF-jB activation, expression of anti-apoptosis proteins
and promoting cell survival [4,5]. When K63 ubiquitination of
RIP1 and TNF-induced NF-jB activation are reduced through cIAP1
and cIAP2 depletion, RIP1 switches its function to that of promot-
ing cell death [23–26]. In this regard, deubiquitinating enzymes
USP21 has been reported to remove K63-linked polyubiquitination
chains from RIP1, thereby, inhibit TNF-a-induced NF-jB activation
[27]. Modulation of RIP1 ubiquitylation by ()-N-[(2S,3R)-3-ami-
no-2-hydroxy-4-phenyl-butyryl]-L-leucine methyl ester (MeBS)
sensitizes cancer cells to TNF-a-induced apoptosis [28]. CLIP-
170-related 59 kDa protein (CLIPR-59) modulates ubiquitination
of RIP1, resulting in the formation of complex-II and thus promot-
ing caspase-8 activation to induce apoptosis by TNF-a [29]. De-
ubiquitinating protease USP2a controls the signaling activity of
the RIP1 by removing its K63-linked ubiquitin chains, culminates
in the conversion of the anti-apoptotic TNFR1 complex I into the
pro-apoptotic TNFR1 complex II and inhibits NF-jB activation
and promotes TNF-induced cell death [30].
In this study, we demonstrate that de-ubiquitinating protease
USP4 negatively regulates RIP1-mediated NF-jB activation and
promotes TNF-a-induced apoptosis through interacting with RIP1
and deubiquitinating K63-linked ubiquitination from RIP1. These
ﬁndings indicate that USP4 has tumor suppressor roles in HNSCC
and suggest USP4 as a potential therapeutic target for HNSCC.
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